Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period

NCT04085523 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.

NCT NCT04085523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04085523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACcomplisH: A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Prepubertal Children With Achondroplasia Followed by an Open-Label Extension Period
Lead sponsor
Ascendis Pharma A/S
Phase
Phase 2
Overall status
Completed
Start date
June 24, 2020
Completion date
October 1, 2024
Enrollment
57 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia